(Q34622294)

3 August 2017

1 reference

title

SGO White Paper on ovarian cancer: etiology, screening and surveillance (English)

1 reference

3 August 2017

1 reference

5

Noah D Kauff

1 reference

3 August 2017

David E Cohn

4

0 references

author name string

John O Schorge

1

1 reference

3 August 2017

Susan C Modesitt

2

1 reference

3 August 2017

Robert L Coleman

3

1 reference

3 August 2017

Linda R Duska

6

1 reference

3 August 2017

Thomas J Herzog

7

1 reference

3 August 2017

language of work or name

English

0 references

publication date

7 August 2010

1 reference

3 August 2017

1 reference

3 August 2017

volume

119

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

7-17

1 reference

Worldwide burden of gynaecological cancer: the size of the problem

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Global cancer statistics, 2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

7 January 2021

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Ovarian surface epithelium: biology, endocrinology, and pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Early events in the pathogenesis of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

The cell of origin of ovarian epithelial tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

New insights into the pathogenesis of serous ovarian cancer and its clinical impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Ovulation and risk of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Menstrual and reproductive factors in relation to ovarian cancer risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Incidence of ovarian cancer of grand multiparous women--a population-based study in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Does Pregnancy Induce the Shedding of Premalignant Ovarian Cells?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Risk factors for ovarian cancer in taiwan: a case–control study in a low-incidence population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Menopausal hormone therapy and risk of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

An analysis of ovarian cancer in the Million Women Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Hormone therapy and ovarian cancer: incidence and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Ovarian cancer incidence in the United States, 1992-1999

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Incidence of ovarian cancer by race and ethnicity in the United States, 1992-1997

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Characteristics relating to ovarian cancer risk: collaborative analysis of seven U.S. case-control studies. Epithelial ovarian cancer in black women. Collaborative Ovarian Cancer Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Dietary risk factors for ovarian cancer: the Adventist Health Study (United States).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Genetic/familial high-risk assessment: breast and ovarian

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Cancer risk in mutation carriers of DNA-mismatch-repair genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Cancer risk associated with germline DNA mismatch repair gene mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Society of Gynecologic Oncologists Education Committee Statement on Risk Assessment for Inherited Gynecologic Cancer Predispositions☆

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Optimal selection of individuals for BRCA mutation testing: a comparison of available methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Validity of models for predicting BRCA1 and BRCA2 mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Patients with an unclassified genetic variant in the BRCA1 or BRCA2 genes show different clinical features from those with a mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Longitudinal CA125 detection of sporadic papillary serous carcinoma of the peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Prophylactic Oophorectomy Reduces Breast Cancer Penetrance During Prospective, Long-Term Follow-Up ofBRCA1Mutation Carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Current approaches in familial colorectal cancer: a clinical perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Biology of epithelial ovarian cancer: implications for screening women at high genetic risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

The preclinical natural history of serous ovarian cancer: defining the target for early detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Ovarian carcinoma diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

ACOG Committee Opinion No. 356: Routine cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Symptoms of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Frequency of symptoms of ovarian cancer in women presenting to primary care clinics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

A randomized study of screening for ovarian cancer: a multicenter study in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Development of an ovarian cancer symptom index: possibilities for earlier detection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Combining a symptoms index with CA 125 to improve detection of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Feasibility of screening for ovarian cancer using symptoms as selection criteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

The search for meaning-Symptoms and transvaginal sonography screening for ovarian cancer: predicting malignancy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Importance of the general practitioner in the early detection of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Prospective study of serum CA-125 levels as markers of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Surveillance of women at high risk for hereditary ovarian cancer is inefficient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Factors associated with return for routine annual screening in an ovarian cancer screening program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Results from four rounds of ovarian cancer screening in a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Diagnostic markers for early detection of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Serum protein markers for early detection of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Use of proteomic patterns in serum to identify ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Retrospective multicenter study of a clinicopathologic analysis of pseudomyxoma peritonei associated with ovarian tumors (KGOG 3005).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

The impact of PET/CT in the management of recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Tumor markers in the management of patients with ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

Pooling of case specimens to create standard serum sets for screening cancer biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.06.003

10.1016/J.YGYNO.2010.06.003

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference